[HTML][HTML] Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases
Background & Aims Therapeutic drug monitoring (TDM) is widely available for biologic
therapies in patients with inflammatory bowel disease (IBD). We reviewed current data and …
therapies in patients with inflammatory bowel disease (IBD). We reviewed current data and …
Infliximab in inflammatory bowel disease
K Papamichael, S Lin, M Moore… - … advances in chronic …, 2019 - journals.sagepub.com
Anti-tumor necrosis factor (TNF) therapy has revolutionized the medical treatment of the
inflammatory bowel diseases (IBD), Crohn's disease (CD), and ulcerative colitis. Twenty …
inflammatory bowel diseases (IBD), Crohn's disease (CD), and ulcerative colitis. Twenty …
Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab
K Papamichael, KA Chachu, RK Vajravelu… - Clinical …, 2017 - Elsevier
Background & Aims Monitoring serum concentrations of tumor necrosis factor antagonists in
patients receiving these drugs as treatment for inflammatory bowel disease (IBD), also …
patients receiving these drugs as treatment for inflammatory bowel disease (IBD), also …
[HTML][HTML] Etiology and management of lack or loss of response to anti–tumor necrosis factor therapy in patients with inflammatory bowel disease
The management of patients with moderate to severe inflammatory bowel disease was
transformed with the arrival of anti–tumor necrosis factor (TNF) therapy. Nevertheless, a …
transformed with the arrival of anti–tumor necrosis factor (TNF) therapy. Nevertheless, a …
Proactive infliximab monitoring following reactive testing is associated with better clinical outcomes than reactive testing alone in patients with inflammatory bowel …
K Papamichael, RK Vajravelu… - Journal of Crohn's …, 2018 - academic.oup.com
Abstract Background and Aims Reactive testing has emerged as the new standard of care
for managing loss of response to infliximab in inflammatory bowel disease [IBD]. Recent …
for managing loss of response to infliximab in inflammatory bowel disease [IBD]. Recent …
Therapeutic drug monitoring during induction of anti–tumor necrosis factor therapy in inflammatory bowel disease: defining a therapeutic drug window
K Papamichael, NV Casteele, M Ferrante… - Inflammatory bowel …, 2017 - academic.oup.com
Anti–tumor necrosis factor (TNF) therapy has revolutionized the treatment of inflammatory
bowel disease (IBD). However, up to 30% of patients with IBD show no clinical benefit and …
bowel disease (IBD). However, up to 30% of patients with IBD show no clinical benefit and …
Association between serum infliximab trough concentrations during maintenance therapy and biochemical, endoscopic, and histologic remission in Crohn's disease
K Papamichael, S Rakowsky, C Rivera… - Inflammatory bowel …, 2018 - academic.oup.com
Background and aim Objective and more rigorous therapeutic outcomes are emerging as
novel targets in Crohn's disease (CD). We investigated the association between …
novel targets in Crohn's disease (CD). We investigated the association between …
[HTML][HTML] Disease monitoring strategies in inflammatory bowel diseases: What do we mean by “tight control”?
L Gonczi, T Bessissow, PL Lakatos - World journal of …, 2019 - ncbi.nlm.nih.gov
In recent years, there has been a critical change in treatment paradigms in inflammatory
bowel diseases (IBD) triggered by the arrival of new effective treatments aiming to prevent …
bowel diseases (IBD) triggered by the arrival of new effective treatments aiming to prevent …
Novel prognostic biomarkers of mucosal healing in ulcerative colitis patients treated with anti-TNF: neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio
L Bertani, F Rossari, B Barberio… - Inflammatory bowel …, 2020 - academic.oup.com
Background Anti-tumor necrosis factor drugs (anti-TNFs) are widely used for the treatment of
ulcerative colitis (UC). However, many patients experience loss of response during the first …
ulcerative colitis (UC). However, many patients experience loss of response during the first …
Therapeutic drug monitoring in IBD: the new standard-of-care for anti-TNF therapy
K Papamichael, AS Cheifetz - … journal of the American College of …, 2017 - journals.lww.com
Anti-tumor necrosis factor (TNF) therapy is effective for the treatment of the inflammatory
bowel diseases (IBD), Crohn's disease (CD) and ulcerative colitis (UC). Nevertheless, up to …
bowel diseases (IBD), Crohn's disease (CD) and ulcerative colitis (UC). Nevertheless, up to …